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Inhaled anesthetics aﬀect protein-protein interaction, but the mechanisms underlying these eﬀects are still poorly understood. We
examined the impact of sevoﬂurane and isoﬂurane on the dimerization of human serum albumin (HSA), a protein with anesthetic
binding sites that are well characterized. Intrinsic ﬂuorescence emission was analyzed for spectral shifting and self-quenching, and
control ﬁrst derivatives (spectral responses to changes in HSA concentration) were compared against those obtained from samples
treated with sevoﬂurane or isoﬂurane. Sevoﬂurane increased dimer-dependent self-quenching and both decreased oligomer-
dependent spectral shifting, suggesting that inhaled anesthetics promoted HSA dimerization. Size exclusion chromatography
and polarization data were consistent with these observations. The data support the proposed model of a reciprocal exchange
of subdomains to form an HSA dimer. The open-ended exchange of subdomains, which we propose occuring in HSA oligomers,
was inhibited by sevoﬂurane and isoﬂurane.
1.Introduction
Inhaled anesthetics aﬀect protein-protein interaction by
disrupting heteromeric [1] and homomeric [2] binding in
some cases and by promoting such interactions in others
[3,4].Theseobservationswarrantfurtherexaminationofthe
interfacial cavities that regulate protein-protein interaction.
Human serum albumin (HSA) provides a useful model
in studying these processes, since it can form dimers [5]
and oligomers [6] in a concentration-dependent manner
[7]. HSA has three homologous domains (I–III), each with
two subdomains (a, b), and inhaled anesthetics bind at
several sites [8–13], one of which is located at the cleft
between subdomains IIa and IIb. This high-aﬃnity site is
at the external side of a cavity that contains the protein’s
only tryptophan (W214), whose properties were tracked
ﬂuorometrically. We recently proposed [14] that this site can
interchange with a site on another HSA forming reciprocal
intersubdomain interactions in a dimeric conformation. The
current study suggests that this process is modulated by
inhaled anesthetics.
2.MaterialsandMethods
2.1. Preparation of Samples. HSA (10mg/mL; Sigma-
Aldrich: A-1653, A-8763) was dissolved in a 10mM sodium
phosphate buﬀer (pH = 7.4), passed through a 0.2μm ﬁlter,
diluted to 0.5–6.0mg/mL and allowed to equilibrate. HSA
was approximately 99% pure as determined by agarose gel
electrophoresis and was essentially free of globulins. Samples
(1.0mL) were treated with and without sevoﬂurane (12μL;
15 minutes on rotator at 22
◦C) and then assayed as described
below. Sevoﬂurane (Abbott; bp: 58.6
◦C; density: 1.52g/cm3)
and isoﬂurane (Hospira; bp: 48.5
◦C; density: 1.50g/cm3)
were layered with argon following use. In order to eﬀectively2 Biochemistry Research International
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Figure 1: Fluorescence spectra at low HSA concentrations. Trypto-
phan ﬂuorescence spectra were obtained as described in Materials
and Methods. Ascending tracings represent HSA at 0.1, 0.2, 0.3, 0.4,
and 0.5mg/mL, respectively. Inset, plot of the AUC (areas under
the curve of entire spectral region) against HSA concentration (r2 =
0.997).
assess the role of agent on HSA self-association at various
protein concentrations, it was necessary for us to use satu-
rating levels of sevoﬂurane and isoﬂurane (12μLi n1 . 0m L
samples), which are immiscible in water and appear as a very
small bolus at the base of the test vessel. Thus, all of the
binding sites that were previously identiﬁed in the literature
would be likely saturated. By attempting to use substantially
lower volumes, a bolus would not form resulting in a coat
on the surface that volatilizes rapidly, leaving an uncertainty
associated with partial binding of agent particularly since
protein concentration was varied. Under the conditions used
in this study, protein denaturation does not occur [15], and
HSA returned to its native state approximately 21 hours after
removal of agent (data not shown).
2.2. Fluorescence Spectroscopy. Tryptophan emission spectra
(e.g., 293nm; em, 300–500nm; 2.5nm slits; 600nm/min;
290nm em cutoﬀ) were obtained at various HSA concen-
trations using a Perkin Elmer LS50B luminescence spec-
trometer. Values for the center of spectral mass (CSM = 
(νFi)di/

Fidi, i = 33.3cm−1), where (ν)i sw a v e n u m b e r
and (Fi) is emission intensity, were calculated from the
emission spectra. They indicate spectral position and reﬂect
the conformational events that change hydration at the
W214 [16]. We calculated a parameter from the spectral
data that reﬂects the magnitude of concentration-dependent
self-quenching [14]. Fluorescence intensities of HSA at
concentrations below 0.5mg/mL were measured as areas
under the curve (Fo =

Fidi), showing a linear increase
with protein concentration (Figure 1) and demonstrating
that there was no self-quenching.
Regression lines (Figure 2) were extended to give a
projected Fo for control and for samples treated with agent.
At higher HSA concentrations, ﬂuorescence (F) intensities
deviated from the linear trajectory (Figure 2) similar to
[HSA] (mg/mL)
























































Figure 2: Observed ﬂuorescence shown relative to projected
unquenched maxima. Extrapolation of regression lines were drawn
from ﬂuorescence data that were obtained at low HSA concentra-
tions from control (solid line), sevoﬂurane-[A] and isoﬂurane [B]-
treated (dashed line) samples. The projected unquenched maxima
arecomparedwithdata(dottedline)observedattheconcentrations
shown (control, closed circles; sevoﬂurane-[A] and isoﬂurane [B]-
treated, open circles). The diﬀerence between the regression lines
and the dotted lines represents IQU.
the self-quenching that occurs in the homomeric assembly
of protein ionophores [17]. The diﬀerence between the
extrapolated linear projection (Fo) and the observed F (IQU
=Fo −F)providesausefulparameter,whichwetermedinte-
gratedquenchunits(IQUs),thatrepresentsthemagnitudeof
quenching at each of the protein concentrations tested.
Solute quenching studies, which use the Stern-Volmer
expression, Fo/F = 1+kQ,w h e r eQ is solute concentration,
assume a bimolecular process [18]. This approach involves
ﬁxing protein concentration, which acts as the ﬂuorophore,
and varies quencher concentration. In our study, we varied
the ﬂuorophore concentration, or HSA, which acts also as
the quencher, making the term, Fo/F, inappropriate. The
diﬀerence term, Fo − F, is commonly used with ﬂuorophoresBiochemistry Research International 3
that self-quench [19] and with diﬀerentially quenched
ﬂuorophores in a single protein [18]. The quenched complex
(dimer/oligomer) is implied by the expression, Fo − F =
IQU, which was tracked as a function of HSA concentration
anddependentuponatleasttwoequilibria(monomer/dimer
and monomer/trimer). IQU and CMS were calculated from
the spectra obtained at various concentrations of HSA in
the presence and absence of sevoﬂurane or isoﬂurane. From
these discrete data, ﬁrst derivatives and second derivatives
were calculated as previously described [14]. The parameters
used in this study (i.e., ﬁrst derivatives) did not lend them-
selves well for investigation of dose-response relationships.
Tryptophan polarization was also measured at ex/em of
293nm/345nm (5nm slits; 10s integrations) and data given
in millipolarization (mP) units.
2.3. Size Exclusion Chromatography. Samples were run
through a gel ﬁltration column (1.5 × 12cm; agarose-based
BioGel A 1.5m ﬁne) using a BioLogic LC system (BioRad).
A sodium citrate (10mM, pH = 6.4) elution buﬀer at a
1.0mL/min ﬂow rate was used with UV detection (280nm
absorbance). Quantitation of monomers and dimers were
performed by either integration of absorbances (Sigma
Plot 11.0) or peak height measurements. Comparisons to
assess the eﬀects of sevoﬂurane involved t-tests or one-way
ANOVAs with Bonferroni posttests. Calibration standards
gamma globulin (158kDa) and ovalbumin (44kDa) were
obtained from BioRad.
3. Results
In order to assess the eﬀects of anesthetic agent on HSA
dimerization, we examined the spectral response to changes
in HSA concentration. The HSA concentration range at
which dimers and oligomers form was previously established
[7, 20]; as HSA increases, the amount of oligomers increases
as well as the size of the multimer from trimer to tetra-,
penta-, and hexamers. Once the trimer forms, it is likely the
multimerization event is monomeric addition to a polymer.
This event can be examined at lower concentrations which
allow for ﬂuorometric analysis without interference due to
higher concentrations. The purpose of this study was to
examine the conformational transitions that are initially
expressed at the concentration range used, which may
provide insight into the behavior of target CNS proteins that
exist in the low micromolar range. In untreated samples,
IQU and CSM increase with HSA concentration exhibiting
a biphasic response [14], suggesting that self-association
aﬀects the W214 and that there are diﬀerent conformational
events for dimerization and for postdimer oligomerization.
With sevoﬂurane, ﬁrst derivatives of IQU were greater than
control during HSA dimerization over the 0.6 to 1.3mg
HSA/mL range (Figure 3(a)), suggesting that sevoﬂurane
promoted protein-protein interactions that enhanced self-
quenching.
Withisoﬂurane,ﬁrstderivativesofIQUweredecreasedat
all concentrations examined (Figure 3(b)). These disparate
observations may be attributed to diﬀerential occupancy
at the subdomain IIa binding site. We previously showed
that second derivatives of IQU from control samples below
1mgHSA/mLdiﬀered reproducibly from that obtained at
concentrations above 1mg HSA/mL [14]. Interestingly, a
comparison of second derivatives of IQU between control
and treated samples exhibited diﬀerences only in the post-
dimeric range from 1.0 to 1.75mg HSA/mL for both agents
(control: 4723 ± 465.6 versus isoﬂurane: 663 ± 582.3, M ±
SEM,P<.0005andcontrol:5772 ±359.5versussevoﬂurane:
3957 ± 161.8, P<. 001). All other comparisons of control
versus treated samples were found to be not signiﬁcant,
suggesting that anesthetic agent exhibited the greatest eﬀect
in the range thought to involve the early forms of oligomers
beginning with trimers [7]. These results were consistent
with those involving CSM. With sevoﬂurane, ﬁrst derivatives
of CSM were less than control in the postdimeric or early
oligomeric phase over the 1.4 to 2.0mg HSA/mL range
(Figure 3(c)), suggesting a stabilization of HSA dimers. With
isoﬂurane,ﬁrstderivativesofCSMwerealsolessthancontrol
in precisely the same postdimeric range from 1.4 to 2.0mg
HSA/mL (Figure 3(d)).
Gel ﬁltration chromatography of sevoﬂurane-treated
samples (1.0mg HSA/mL) exhibited a diﬀerent distribution
of monomers and dimers compared with control (Fig-
ure 4(a)). Sevoﬂurane treatment promoted dimer formation
(P<. 05). Additionally, the dimers from sevoﬂurane-treated
samples eluted earlier than those of control (P<.04). The
relative amount of monomers was less with sevoﬂurane
(P<.03), suggesting a change in the monomer-dimer equi-
librium. Isoﬂurane showed a similar eﬀect (Figure 4(b))
at 0.675mg BSA/mL with the predicted shift in protein
distribution to favor the dimer in the presence of isoﬂurane.
At these concentrations there were no detectable diﬀerences
in the amount of higher-order oligomers.
WhenHSA(10mg/mL)wastreatedwithsevoﬂuraneand
then analyzed for tryptophan ﬂuorescence polarization, we
observed a decrease relative to control (Figure 5) in either
low (control: 227.0mP; plus sevoﬂurane, 224.1, P<. 02) or
high ionic strength (control: 228.9; plus sevoﬂurane: 225.7,
P<. 005), consistent with a destabilization of higher-order
oligomers in favor of the smaller more mobile dimer.
4. Discussion
The three homologous domains of HSA exist in a V-shape.
The apposing lobes represent domains I and III. The vertex
represents the interface of subdomains IIa and IIb, which
has a cluster of hydrophobic residues, including V216, V231
(helix 2 and 3, subdomain IIa) and L331, L347 (helix 2 and
3, subdomain IIb), and has a salt bridge between residue
R209 (helix 2, subdomain IIa) and residues D324 and E354
(helix 2 and 3, subdomain IIb). We previously proposed [14]
that dimerization results from a reciprocal intersubdomain
switch between two HSA molecules, such that subdomains
IIa and IIb of one HSA interact with the complementary
subdomains(IIbandIIa)ofanotherHSA.Themodelfurther
suggests that higher-order oligomers emerge from sequential
intersubdomain exchanges from a unique trimeric structure
thathasfreesubdomainscapableofextension.Itisfortuitous4 Biochemistry Research International
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Figure 3: Eﬀects of sevoﬂurane and isoﬂurane on the ﬁrst derivatives of CSM and IQU. HSA was treated with (open circles) and without
(ﬁlledcircles)sevoﬂurane(a)and(c)andisoﬂurane(b)and(d)priortomeasuringﬂuorescencespectraanddeterminingtheﬁrstderivatives
of IQU (a) and (b) and CSM (c) and (d). Data were from four independent experiments and presented as M ± SEM. Asterisks indicate
diﬀerences (P<. 05) due to anesthetic agent.
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Figure 4: Anesthetic agents promote albumin dimerization. HSA[A] and BSA[B] were treated with (red) and without (black) agent
(sevoﬂurane [A] and isoﬂurane [B]) prior to size exclusion chromatography and quantitation of the peaks. Tracings in (a) are smoothed
curves that represent averages from four independent experiments. Tracings in (b) are from a representative experiment. Column size and
ﬂow rates diﬀered slightly between (a) and (b) with gamma globulin (158kDa) eluting at 13.1 and 19.2 minutes, respectively.Biochemistry Research International 5
that HSA has a single tryptophan residue (W214) that is on
helix2insubdomainIIa.AlthoughW214isorientedinternal
to subdomain IIa, the ﬂuorometric properties are aﬀected
by changes in protein concentration in predictable ways that
cause self-quenching and spectral shifts [14], suggesting that
the vertex plays a role in protein-protein interaction. Others
have also suggested that W214 is at the interface of the HSA
dimer [21].
Interestingly, halothane binds [10] at the site represented
by the vertex. Three halothane molecules bind to this site
and are within 5 angstrom of the residues described above
(1E7C, pdb). Inhaled anesthetics therefore may modulate
eventssuchastheproposedmechanismofHSAdimerization
and oligomer formation. We examined whether anesthetic
agent aﬀected protein-protein interaction by comparing ﬁrst
derivatives of IQU, which measures self-quenching, and
CSM, which measures ﬂuorophore hydration, over a range
of HSA concentrations in the presence and absence of
agent. The diﬀerences that we observed suggest that the
proposed IIa/IIb intersubdomain switch is inﬂuenced by
inhaled anesthetics.
Since spectral changes were compared as ﬁrst derivatives,
meaning that they were a function of changes in protein
concentration in the range that dimerization and early
oligomers form, the simplest interpretation would be that
homomeric associations contributed to these ﬁndings. Any
other interpretation would be inappropriate. Our specula-
tion is limited to the mechanisms of subunit interaction that
may contribute to the changes. And since HSA contains only
one single tryptophan, its microenvironment is implicated
in the proposed mechanism. Sevoﬂurane increased the IQU
response (Figure 3(a)) over a range of HSA concentrations
(0.68–1.25mg/mL) that is associated with dimer formation
[7, 20, 22]. It was previously shown that self-quenching
of intrinsic ﬂuorescence occurs upon dimerization of β-
lactoglobulin[23].Theself-quenchingindicatesacloseprox-
imity of native ﬂuorophores (W214) on neighboring HSA
molecules during dimerization. This observation suggests
that sevoﬂurane increased the concentration-dependent self-
quenching by promoting HSA dimerization in a manner
consistent with the proposed mechanism. With isoﬂurane,
ﬁrst derivatives of IQU were decreased at all concentrations
examined (Figure 3(b)), likely a feature of the greater
quenching eﬀects of isoﬂurane on monomeric HSA (Fig-
ure 2) that occur independent of changes in HSA concen-
tration. Nevertheless, in examining second derivatives of the
IQU parameter, both sevoﬂurane and isoﬂurane exhibited
similar eﬀects at the postdimeric concentrations of HSA,
suggestive of a stabilization of the HSA dimeric structure
or a destabilization of early oligomers. This observation
is supported by size exclusion chromatography of HSA
samples (1.0mg/mL) treated with sevoﬂurane (Figure 4(a))
that demonstrated increased dimer and decreased monomer
formation. The decrease in elution time of the dimer may be
due to added mass, which is consistent with the previously
documented eight molecules of anesthetic agent bound per
HSA subunit [10], contributing about 3.2kD to the dimer.
Alternately, the dimer conformation in the presence of agent

























HSA (10mg/mL) was treated with sevoﬂurane and then analyzed
for ﬂuorescence polarization and compared against control with
(gray bars) and without (black bars) isotonic saline. Data are
from multiple readings from two independent experiments and
presented as M ± SEM.
expansion and consistent with the previous observations
[12].
Sevoﬂurane and isoﬂurane also decreased the CSM
response (Figures 3(c) and 3(d))o v e rt h er a n g eo fH S A
concentrations (1.4 to 2.0mg/mL), where trimers begin to
appear [7]. This agent-induced decrease in CSM response
occurred in the post Kd (HSA monomer-dimer) concentra-
tion range. The CSM response, which is the concentration-
dependent blue-shift of the W214 emission spectrum, indi-
cates a loss of hydration [16] in this region due to the
protein-protein interaction in oligomerization [24, 25]. Our
observation suggests that sevoﬂurane and isoﬂurane brings
about a stabilization of the dimer, a destabilization of the
early trimers, or an inhibition of metastable oligomers.
Support for this suggestion is in the observation that
sevoﬂurane decreased the ﬂuorescence polarization of HSA
samples (Figure 5) .T h el i t e r a t u r ep r o v i d e se v i d e n c et h a t
self-quenchingofﬂuorescein-labeledHSAisaccompaniedby
self-depolarization [26], indicating homotransfer.
Protein-protein interaction is a process that normally
regulates the function of many neuronal membrane proteins
[27]andmaybethemechanismbywhichinhaledanesthetics
alter the biological activity of target proteins. Some of the
eﬀects that we examined with HSA may be generalized
to CNS receptor targets, such as the GABAA receptor
[28]. It would be of interest to determine if the GABAA
r e c e p t o ra l s ou n d e r g o e sr e c i p r o c a ls u b d o m a i ne x c h a n g e .
Dimerization involves interfacial cavities whose dimensions
and properties are dependent on the packing density of
protein side chains [29]. Sevoﬂurane or isoﬂurane may alter
the geometry of these cavities, stabilizing the quaternary
structure of proteins in a unique manner. Interestingly,
parvalbumin reaches a monomer-dimer or monomer-trimer
equilibrium depending on presence of divalent cations [30].
Furthermore, static quenching of W214 by nearby residues
may occur [31], suggesting a conformational realignment6 Biochemistry Research International
from a reciprocal exchange or swap (i.e., dimer) to an open-
ended exchange of subdomains (i.e., trimer as a nucleation
center for oligomerization).
Of the multiple sites to which anesthetic agent bind,
the drug binding sites I and II at subdomain IIa and
IIIa, respectively, and the intersubdomain cleft between
subdomains IIa and IIb are the sites most studied in the
literature. The intersubdomain cleft interfacing subdomains
IIa and IIb is likely the site to which the agents examined
in the present study had their eﬀect, as this site suggests a
swapping of subdomains that would have an impact on the
tryptophan signal. The concentration-independent eﬀects
of isoﬂurane diﬀered from sevoﬂurane and their IQU ﬁrst
derivatives also diﬀered, suggesting that these two agents
likely show diﬀerent aﬃnities to the internal cavity of the
subdomain IIa, which would directly quench the tryptophan
signal. Nevertheless, the corroboration of the CSM data and
the second derivatives of IQU support the working model
that upon binding to the interface at subdomains IIa and
IIb dimerization appears favored over the early oligomeric
structures.
HSA dimerizes more readily without fatty acids [5], and
inhaled anesthetics displace fatty acids from this intersub-
domain cleft [10], suggesting that the formation of these
interfacial cavities may be due to acyl chain displacement.
This mechanism may be applicable to neuronal membrane
proteins.
Isoﬂurane, which binds to drug binding site II in
subdomain IIIa at the Y411 residue [32], also binds to the
interdomain cleftandlikely drugbinding siteIin subdomain
IIa aﬀecting tryptophan signal [11]. We observed a large
quenching of the monomeric HSA (Figure 2) consistent with
[11]. Sevoﬂurane and isoﬂurane showed identical eﬀects
on CSM suggesting similar binding proﬁles (Figure 3).
Sevoﬂurane also aﬀected W214 ﬂuorescence in a manner
that was independent of changes in protein concentration.
Monomeric HSA (0.5mg/mL) in the presence of sevoﬂurane
exhibited a 13.8% decrease in emission intensity and a blue-
shiftedspectrum(lambda-max:351.3nm,control;349.2nm,
plus sevoﬂurane). These direct aﬀects indicated that sevoﬂu-
rane did also bind to drug-binding site I, which is an internal
cavity of subdomain IIa. This observation is consistent with
the binding of isoﬂurane and halothane in HSA [11], though
isoﬂurane had a greater quenching eﬀect on monomeric
HSA (Figure 2). In our study, these measurements were used
to normalize the data that assessed the eﬀects of protein
concentration.
We observed that inhaled anesthetics had concentration-
dependent eﬀects on HSA in that dimerization was pro-
moted, as evidenced by ﬁrst and second derivatives of
IQU and that postdimer oligomerization was inhibited as
evidenced by a decrease in ﬁrst derivatives of CSM at
1.4mg HSA/mL. The data support a dimer model that
exhibits a reciprocal intersubdomain conformation that
must rearrange to generate oligomers. Reciprocal exchange
of subdomains was previously identiﬁed as a mechanism of
homo- and heterodimerization of transcriptional regulators
containing helix-loop-helix domains [33], which show simi-
larities to the behavior of helix 2 and 3 of HSA subdomains
IIa and IIb, and may be a general mechanism for protein
assembly [34].
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